BPA for orentiram, remodulin, tyvaso, and unituxin. Base year with four one year option periods
Ended Awarded Last action
- Contract number
- 36E79720A0005
- Awardee
-
United Therapeutics Corp UEI KK5FBFA43JS7
- Awarding agency
-
National Acquisition Center
Headquarters, Department of Veterans Affairs
- Task orders
- 0
Award facts
- Opportunity
-
- VA797P12Q0002 Solicitation number
- Last date to order 100% complete
- IDV ceiling
- $60,000,000.00
- Award type
- Single award
- Who can order
- Only the awarding agency
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
Award details come from SAM.gov/FPDS.
About this IDV
This Blanket Purchase Agreement was awarded by the Department of Veterans Affairs National Acquisition Center to United Therapeutics Corporation. The BPA utilizes the Pharmaceuticals and Drugs GSA Schedule to provide Orentiram, Remodulin, Tyvaso, and Unituxin for an estimated $60 million over a base year and four option years.
The BPA aims to procure pharmaceutical products for treatment of pulmonary arterial hypertension and neuroblastoma. Orentiram, Remodulin, and Tyvaso are medications administered via inhalation or injection to treat pulmonary arterial hypertension, a type of high blood pressure that affects the arteries in the lungs and heart. Unituxin is a chemotherapy drug used to treat high-risk neuroblastoma, a type of cancer that forms in certain types of nerve tissue. These medications will likely be provided to veterans receiving care through VA medical centers and clinics nationwide over the five-year period of performance.
No set-aside provisions were applied to this single-award BPA. As the VA's goal is to provide comprehensive healthcare for enrolled veterans, this agreement will help ensure veterans have reliable access to specialized drugs that treat serious medical conditions through the contracted supplier, United Therapeutics Corporation, over the life of the BPA.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Legal Contract Cancellation | $0 | |
| Original award | $0 |
Quick answers
Who was awarded contract 36E79720A0005?
36E79720A0005 was awarded to United Therapeutics Corp by National Acquisition Center (Headquarters) on January 24, 2020.
How much is contract 36E79720A0005 worth?
36E79720A0005's own ceiling is $60,000,000.
Who can order from contract 36E79720A0005?
36E79720A0005 is a single award blanket purchase agreement. Only the awarding agency can place orders on it.
Is contract 36E79720A0005 under another contract?
Yes. 36E79720A0005 is a blanket purchase agreement under V797D40275, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36E79720A0005 competed?
The extent of competition for 36E79720A0005 was full and open competition. The government received 1 offer.
On GovTribe
See this IDV's full record
- Every order and transaction
- The awardee's other awards and teaming partners
- Similar IDVs and recompete opportunities
- Ask GovTribe AI about this IDV